Blog

Essure Sales to be Discontinued in Canada

Bayer has announced it will discontinue the sale of the Company’s controversial permanent birth control device for women – Essure – in Canada.  This follows similar actions taken by the Company in the UK and Finland, and an outright ban of Essure by the National Health Surveillance Agency (ANVISA) in Brazil.  According to a recent article, Essure remains the subject of a potential class-action lawsuit in Canada involving hundreds of women.  Many of these individuals have undergone hysterectomies due to complications related to Essure.

If you or a loved one suffered complications after receiving an Essure implant, please contact us at 888-984-7988 for a confidential evaluation of your potential claim.

Essure to be Pulled from Markets in UK & Finland

Last week, Bayer UK issued a press release revealing plans to discontinue the sale and distribution of Essure in the UK as of September 01, 2017. Days earlier Bayer announced its decision to end Essure sales in Finland at the end of June 2017. These announcements come on the heels of the American Food and Drug Administration’s order for a “black box warning” to appear on the Essure birth control device as a result of nearly 10,000 reports of adverse events.

If you or a loved one suffered complications after receiving an Essure implant, please contact us at 888-984-7988 for a confidential evaluation of your potential claim.

Study of Pinnacle Total Hip Replacements (THR) Concludes High Failure Rate at 10-years

On June 1st at the EFORT Congress in Vienna, PhD student Gulraj S. Matharu of the University of Oxford presented findings from a study of Pinnacle’s metal-on-metal total hip replacements. He concluded that statistically, patients who underwent THR with the Pinnacle prosthesis had a significantly greater risk of implant failure if they had bilateral surgery or were operated on in or after 2006. “This supports the recent and serious concerns about potential manufacturing differences in more recent years,” Matharu said.

If you or a loved one has experienced complications after receiving a metal-on-metal hip implant, please contact us at 888-984-7988 for a confidential evaluation of your potential claim.

Stryker to Move Forward With Payments Associated with 2016 Settlement Program

In May 2017, Stryker Corporation announced that it will begin making payments to eligible patients enrolled in a 2016 settlement program associated with the company’s metal-on-metal hip replacements. The 2016 settlement program compensates patients who underwent surgery to replace their Rejuvenate Modular-Neck hip stem or ABG II Modular Neck hip stem before December 19, 2016.

If you or a loved one has experienced complications after receiving a metal-on-metal hip implant, please contact us at 888-984-7988 for a confidential evaluation of your potential claim.

Stryker LFIT V40 MDL Underway in Boston

A recently created multidistrict litigation, or MDL, has centralized product liability cases involving injuries related to Stryker LFIT V40 femoral heads, a component of prosthetic hip replacement devices. In an April 5, 2017 order from the Judicial Panel on Multidistrict Litigation, the cases in the MDL were transferred to Massachusetts District Court, before Judge Indira Talwani. The MDL is designed to streamline pre-trial proceedings and eliminate duplicative discovery efforts. The proceeding’s first status conference is scheduled for May 16, 2017.

Each of the lawsuits in the MDL similarly allege that the Stryker LFIT V40 femoral head component caused plaintiffs debilitating side-effects such as metallosis, tissue damage, device fracture, and other problems that have led to painful hip revision surgery. If you or a loved one experienced complications after receiving a metal-on-metal hip implant, please contact us at 888-984-7988 for a confidential evaluation of your potential claim.

Real Time Analytics